CJC-1295 + Ipamorelin Synergy: Research Guide | Peptide Intel Hub

CJC-1295 is a GHRH (growth-hormone-releasing-hormone) analog: it binds the GHRH receptor on anterior-pituitary somatotrophs and raises intracellular cAMP, primarily increasing the amplitude of each natural GH pulse. Ipamorelin is a GHRP (growth-hormone-releasing-peptide) — a selective ghrelin/GHS-R1a agonist that acts through a phospholipase-C / IP3 pathway, primarily increasing the frequency and trough-to-peak height of GH pulses. The two receptors sit on the same cell type but use different second-messenger cascades, which is the structural reason the response is additive rather than redundant.

In published in-vivo research models, co-administration of a GHRH analog with a GHRP produces a GH pulse that is consistently larger than either compound alone — often described in the literature as a 'synergistic' rather than 'additive' release. The mechanistic explanation usually cited is dual second-messenger activation (cAMP from GHRH-R plus IP3 from GHS-R1a) combined with GHRP-driven suppression of somatostatin tone, which removes the natural brake on GH release. The pulsatile shape of the response — rather than a flat elevation — is one reason the pairing is preferred in research models that try to approximate physiological GH kinetics.

Research-grade CJC-1295 is supplied in two forms. No-DAC (often called Modified GRF 1-29) has a half-life measured in minutes, producing a discrete pulse that pairs cleanly with Ipamorelin's own short window. With-DAC adds a drug-affinity-complex that binds serum albumin and extends the half-life to roughly six to eight days, producing sustained GHRH-R occupancy rather than a discrete pulse. Most synergy-focused research literature uses the No-DAC form precisely because the pulse shape is closer to native GH kinetics; With-DAC is more often referenced in chronic-exposure tonic-stimulation models.

Ipamorelin is the most-selective ghrelin-receptor agonist among the commonly studied GHRPs. Compared with GHRP-2 or GHRP-6, Ipamorelin shows minimal cross-activation of cortisol, prolactin or ACTH pathways in research models — a 'clean' GH-selective profile. That selectivity is the main reason CJC-1295 + Ipamorelin became the reference research pairing rather than CJC-1295 + GHRP-6: it isolates the GH-axis response from confounding endocrine read-outs in published in-vitro and in-vivo data.

CJC-1295 No-DAC has a circulating half-life of roughly thirty minutes in research models; Ipamorelin's half-life is approximately two hours. When the two are co-administered the GHRH-R occupancy from CJC-1295 No-DAC falls inside Ipamorelin's active window, which is why research protocols generally schedule both at the same time-point. With-DAC CJC-1295 changes that picture entirely — its multi-day half-life produces a tonic GHRH-R signal that any pulse of Ipamorelin lands on top of, rather than a discrete co-administered pulse.

Both compounds ship lyophilised and are stored at 2–8°C until reconstitution with bacteriostatic water. Ipamorelin's reconstituted in-use stability window is typically reported in the two-to-four-week range refrigerated; CJC-1295 No-DAC is similar. Aliquot before any freeze: the single most common cause of measurable potency loss in either compound is repeat freeze-thaw cycling rather than ordinary refrigerated storage.

Reputable batches of CJC-1295 (No-DAC and With-DAC) and Ipamorelin are released only after independent third-party verification. Janoshik Analytical is a common verifier, with orthogonal laboratories used when batch chemistry calls for a second method. A typical release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight, documented in a lot-matched certificate of analysis.

For pulsatile-GH-release research that mirrors physiological kinetics, the CJC-1295 No-DAC + Ipamorelin pairing is the published reference. For chronic GHRH-R tonic-exposure models — for example, long-duration metabolic or body-composition studies — CJC-1295 With-DAC paired with Ipamorelin is the more common reference. Both pairings ship from the Regena Peptides library with current batch data; researchers should always cross-reference the protocol's own controls and current literature before designing an in-vitro or in-vivo study.